Georgantopoulos P, et al. - Researchers examined 24,198 chronic lymphocytic leukemia (CLL) cases to determine incidence of and risk factors for major hemorrhage (MH) in CLL patients before introduction of newer CLL therapies such as ibrutinib, which includes bleeding risk. The participants were treated in the Veterans Health Administration (VA) system from 1999 to 2013, prior to FDA approval of ibrutinib as CLL therapy. The estimated incidence of MH was 1.9/100 person-years, with cumulative incidences of 2.3%, 5.2%, and 7.3% by year 1, 3, and 5, respectively. A duration of 2.8 years was documented as median time from CLL diagnosis to MH. In multivariate analyses, increased MH risk was observed in relation to concurrent anticoagulant and antiplatelet use, anticoagulant use only, and antiplatelet use only vs not receiving those medications; increased MH risk was observed in relation to being nonwhite, male, having MH history, renal impairment, anemia, thrombocytopenia, and alcohol abuse.